Press Release

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today completed certain transactions contemplated by the arrangements reached with the former shareholders of Talent Biotechs Ltd. of Israel (“Talent”) on terms that were previously announced in...

Independent DSMB Approves Dose Escalation for Second Cohort in Phase 2 Clinical Study Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced additional positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol...

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 13,085,677 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under...

Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) today announced that it has granted stock options on January 25, 2019 to certain directors and employees of the Company. The stock options have an exercise price of $0.085 per...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) is pleased to announce the closing of its private placement previously announced on January 11, 2019 of 3,558,573...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) is pleased to announced the closing of its previously announced private placement of 11,532,000 common shares of the Company...

Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) announced that Echelon Wealth Partners, Inc. (“Echelon”) has initiated research coverage on Kalytera with a speculative "Buy" rating and a one-year price target of $0.30 per share. The Company is...

Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) today announced that the Company has elected to issue 9,387,831 common shares of the Company ("Common Shares") to The Salzman Group in payment of invoices issued under the payments agreement...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) announced today that it is proceeding with a private placement under which it intends to sell up to...